These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 9623118)

  • 1. [Neuropsychiatric adverse effects attributed to use of oxybutynin].
    t'Veld BA; Kwee-Zuiderwijk WJ; van Puijenbroek EP; Stricker BH
    Ned Tijdschr Geneeskd; 1998 Mar; 142(11):590-2. PubMed ID: 9623118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxybutynin efficacy in the treatment of primary enuresis.
    Lovering JS; Tallett SE; McKendry JB
    Pediatrics; 1988 Jul; 82(1):104-6. PubMed ID: 3288951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Adverse effects of oxybutynin chloride (Ditropan). Evaluation of the official survey of Regional Pharmacovigilance Centers].
    Jonville AP; Dutertre JP; Autret E; Barbellion M
    Therapie; 1992; 47(5):389-92. PubMed ID: 1299977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships.
    Gupta SK; Sathyan G; Lindemulder EA; Ho PL; Sheiner LB; Aarons L
    Clin Pharmacol Ther; 1999 Jun; 65(6):672-84. PubMed ID: 10391673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic effects of intrarectal administration of oxybutynin].
    Radziszewski P; Borkowski A
    Wiad Lek; 2002; 55(11-12):691-8. PubMed ID: 12715351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of oxybutynin treatment on cognition in children with diurnal incontinence.
    Sommer BR; O'Hara R; Askari N; Kraemer HC; Kennedy WA
    J Urol; 2005 Jun; 173(6):2125-7. PubMed ID: 15879864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term prospective randomized study comparing two different regimens of oxybutynin as a treatment for detrusor overactivity.
    Salvatore S; Khullar V; Cardozo L; Milani R; Athanasiou S; Kelleher C
    Eur J Obstet Gynecol Reprod Biol; 2005 Apr; 119(2):237-41. PubMed ID: 15808387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Assessment of the use of oxybutynin hydrochloride (Pollakisu tablets) in the elderly].
    Uchibayashi T; Nakajima K; Nihino A; Hisazumi H
    Hinyokika Kiyo; 1991 Sep; 37(9):1077-85. PubMed ID: 1785418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between oxybutynin and neuropsychiatric adverse effects not confirmed in daily practice.
    Movig KL; Egberts AC; Lenderink AW; Leufkens HG
    J Am Geriatr Soc; 2001 Feb; 49(2):234-5. PubMed ID: 11207885
    [No Abstract]   [Full Text] [Related]  

  • 10. [Oxybutynin chloride in pediatrics: extenuating circumstances].
    Aubert D
    Arch Fr Pediatr; 1988 May; 45(5):375-6. PubMed ID: 3415420
    [No Abstract]   [Full Text] [Related]  

  • 11. [Adverse effects of oxybutynin chloride (Ditropan) in pediatrics].
    Jonville AP; Dutertre JP; Barbellion M; Autret E
    Arch Fr Pediatr; 1993 Jan; 50(1):27-9. PubMed ID: 8507135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability.
    Kilic N; Balkan E; Akgoz S; Sen N; Dogruyol H
    Int J Urol; 2006 Feb; 13(2):105-8. PubMed ID: 16563131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome.
    Abrams P; Cardozo L; Chapple C; Serdarevic D; Hargreaves K; Khullar V;
    Int J Urol; 2006 Jun; 13(6):692-8. PubMed ID: 16834644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Management of hyposalivation caused by oxybutynin chloride in the treatment of the unstable bladder].
    Arango Toro O; Nohales Taurines G; Cortadellas Angel R; Castro Santamaría R; Gelabert Mas A
    Actas Urol Esp; 1998 Feb; 22(2):124-30. PubMed ID: 9586268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary evaluation of a new controlled-release oxybutynin in urinary incontinence.
    Radomski SB; Caley B; Reiz JL; Miceli PC; Harsanyi Z; Darke AC
    Curr Med Res Opin; 2004; 20(2):249-53. PubMed ID: 15006020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Use of driptan (oxybutinin) in patients with urgent forms of urination disorders].
    Loran OB; Pushkar' DIu; Tevlin KP
    Urol Nefrol (Mosk); 1998; (6):24-6. PubMed ID: 10051823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low dose oxybutynin for the unstable bladder.
    Malone-Lee J; Lubel D; Szonyi G
    BMJ; 1992 Apr; 304(6833):1053. PubMed ID: 1586797
    [No Abstract]   [Full Text] [Related]  

  • 18. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder.
    Goldenberg MM
    Clin Ther; 1999 Apr; 21(4):634-42. PubMed ID: 10363730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case 7: the addled nonagenarian.
    Shader RI; Oesterheld JR
    J Clin Psychopharmacol; 1995 Oct; 15(5):378. PubMed ID: 8830074
    [No Abstract]   [Full Text] [Related]  

  • 20. Should we switch over to tolterodine in every child with non-neurogenic daytime urinary incontinence in whom oxybutynin failed?
    Yucel S; Akkaya E; Guntekin E; Kukul E; Danisman A; Akman S; Baykara M
    Urology; 2005 Feb; 65(2):369-73. PubMed ID: 15708055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.